Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Orchard Therapeutics Plc ADR (ORTX)

Orchard Therapeutics Plc ADR (ORTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 62,915
  • Shares Outstanding, K 125,905
  • Annual Sales, $ 1,680 K
  • Annual Income, $ -144,580 K
  • 60-Month Beta 1.19
  • Price/Sales 36.08
  • Price/Cash Flow N/A
  • Price/Book 0.35
Trade ORTX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.22
  • Most Recent Earnings -0.35 on 05/12/22
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 789.69% ( -208.97%)
  • Historical Volatility 69.72%
  • IV Percentile 98%
  • IV Rank 78.33%
  • IV High 998.67% on 05/20/22
  • IV Low 34.25% on 09/15/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 0
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 1,208
  • Open Int (30-Day) 3,530

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.25
  • Number of Estimates 4
  • High Estimate -0.24
  • Low Estimate -0.26
  • Prior Year -0.29
  • Growth Rate Est. (year over year) +13.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4120 +21.29%
on 05/12/22
0.6784 -26.34%
on 04/25/22
-0.1503 (-23.12%)
since 04/22/22
3-Month
0.4120 +21.29%
on 05/12/22
0.9669 -48.32%
on 02/25/22
-0.4290 (-46.19%)
since 02/23/22
52-Week
0.4120 +21.29%
on 05/12/22
5.6300 -91.12%
on 05/24/21
-5.0203 (-90.95%)
since 05/21/21

Most Recent Stories

More News
Orchard Therapeutics Announces Reimbursement Agreement Making Libmeldy Available for All Eligible MLD Patients in Italy

BOSTON and LONDON, April 11, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced it has reached...

ORTX : 0.4997 (+4.10%)
Orchard Therapeutics Extends Runway into 2024, Focusing HSC Gene Therapy Platform Exclusively on Severe Neurometabolic Diseases and Research Platform

Libmeldy European launch momentum building with multiple MLD patients treated and strong recognition of value proposition; U.S. BLA filing of OTL-200 on...

ORTX : 0.4997 (+4.10%)
Orchard Therapeutics Announces Multiple Presentations at WORLDSymposium™ 2022

BOSTON and LONDON, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today outlined five...

ORTX : 0.4997 (+4.10%)
Orchard Therapeutics Announces Historic Agreement Making Libmeldy Available by NHS England for MLD Patients

First-ever lentiviral hematopoietic stem cell gene therapy approved for reimbursement by NHS England Two children with early-onset MLD recently treated...

ORTX : 0.4997 (+4.10%)
Orchard Therapeutics Announces Publication in The Lancet of Long-term Clinical Outcomes with Libmeldy for the Treatment of Children with Early-onset MLD

Administration of one-time hematopoietic stem cell (HSC) gene therapy resulted in sustained, clinically meaningful benefits by preserving cognitive...

ORTX : 0.4997 (+4.10%)
Orchard Therapeutics Announces Recent Commercial and Regulatory Progress for Late-stage HSC Gene Therapy Programs and Outlines Key 2022 Milestones

Launch Momentum Building for Libmeldy® in Europe with Health Technology Assessments Progressing Favorably and Treatment Underway for Multiple Commercial...

ORTX : 0.4997 (+4.10%)
Orchard Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

BOSTON and LONDON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company...

ORTX : 0.4997 (+4.10%)
Orchard Therapeutics Announces New England Journal of Medicine Publication of Interim Proof-of-concept Study Results of OTL-203 for Hurler Syndrome

100 percent overall survival with median follow-up of two years post-treatment with HSC gene therapy Preliminary findings show promising metabolic and...

ORTX : 0.4997 (+4.10%)
Orchard Therapeutics to Present at Virtual Investor Conferences in November 2021

BOSTON and LONDON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that members of...

ORTX : 0.4997 (+4.10%)
Orchard Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Business Updates

Updates from OTL-201 Clinical Proof-of-Concept Study in MPS-IIIA and OTL-204 Preclinical Study for GRN-FTD at ESGCT Showcase Potential for HSC Gene Therapy...

ORTX : 0.4997 (+4.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Orchard Therapeutics plc is a biopharmaceutical company. It offers medical research, gene therapy and inherited disorder treatment services which transforms the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies. Orchard Therapeutics plc is based...

See More

Key Turning Points

3rd Resistance Point 0.5265
2nd Resistance Point 0.5132
1st Resistance Point 0.5065
Last Price 0.4997
1st Support Level 0.4865
2nd Support Level 0.4732
3rd Support Level 0.4665

See More

52-Week High 5.6300
Fibonacci 61.8% 3.6367
Fibonacci 50% 3.0210
Fibonacci 38.2% 2.4053
Last Price 0.4997
52-Week Low 0.4120

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar